Latest Antiandrogens Stories
TOKYO and SAN FRANCISCO, April 2, 2015 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc.
HORSHAM, Pa., March 30, 2015 /PRNewswire/ -- The U.S.
VANCOUVER, Canada and HOUSTON, TX, March 2, 2015 /PRNewswire/ - ESSA Pharma Inc.
VANCOUVER, Canada and HOUSTON, TX, Feb. 27, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd.
HOUSTON, TX and VANCOUVER, Feb. 25, 2015 /PRNewswire/ - ESSA Pharma Inc.
VANCOUVER, Jan. 26, 2015 /PRNewswire/ - ESSA Pharma Inc.
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.
- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin
- An armed gangster.